Seattle Genetics Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
158.79 M |
Public Float |
106.67 M |
Seattle Genetics Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$0.78 |
Market Cap |
$11.14 B |
Shares Outstanding |
161.32 M |
Public Float |
158.22 M |
Address |
21823 30th Drive SE Bothell Washington 98021 United States |
Employees | - |
Website | http://www.seattlegenetics.com |
Updated | 07/08/2019 |
Seattle Genetics, Inc. engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its product ADCETRIS is an antibody-drug encompassing several settings for the treatment of relapsed Hodgkin lymphoma, for relapsed systemic anaplastic large cell lymphoma, or sALCL, and for certain types of cutaneous T-cell lymphoma, or CTCL. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. |